Sava Infond’s Sarepta Therapeutics SRPT Stock Holding History

Sava Infond’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,500	Closed	-$77K	–	216
2025 Q2	$77K	Hold	4,500	–	–	0.01%	201
2025 Q1	$287K	Buy	4,500 +1,500	+50%	+$158K	0.05%	143
2024 Q4	$365K	Buy	+3,000	New	+$368K	0.06%	135

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sava Infond's SRPT Position: Q3 2025 in Review

Sava Infond sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 4,500 shares — an estimated $77K sold.

Sava Infond first reported a position in SRPT in Q4 2024 and held it in 3 quarters. The position peaked at $365K in Q4 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Sava Infond reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Sava Infond sold 4,500 Sarepta Therapeutics shares in Q3 2025, an estimated $77K.
Sava Infond first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 3 quarters.
Sava Infond's Sarepta Therapeutics position peaked at $365K in Q4 2024.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Sava Infond's 13F filing for Q3 2025, filed 10 Nov 2025.